Abstract:Colorectal cancer (CRC) remains a remarkable challenge despite considerable advancements in its treatment, due to its high recurrence rate, metastasis, drug resistance, and heterogeneity. Molecular targets that can effectively inhibit CRC growth must be identified to address these challenges. Therefore, we aim to reveal the regulatory effect of ribosomal protein L22-like 1 (RPL22L1) on the proliferation and apoptosis of CRC cells and its potential mechanism. We detected the expression of RPL22L1 from the Cancer Genome Atlas, Gene Expression Omnibus and UALCAN databases. The effects of RPL22L1 on CRC growth and migration were determined by knocking down RPL22L1 in human CRC cell lines and those on the cell cycle and apoptosis using flow cytometry. The influence of RPL22L1 knockdown on xenograft tumor growth was verified in vivo. The potential RPL22L1 mechanisms in promoting cancer were predicted with RNA sequencing (RNAseq). The molecular mechanism of enhanced apoptosis and cell cycle arrest in RPL22L1 knockdown was revealed using real-time reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) and Western blotting. The present study reveals a considerable upregulation of RPL22L1 expression in CRC as well as in diverse tumor tissues, and most cells within the CRC tumor microenvironment (TME) demonstrate RPL22L1 expression. Notably, this elevated expression level of RPL22L1 exhibits a strong association with an unfavorable prognosis among patients diagnosed with CRC (P < 0.05). Furthermore, the association between RPL22L1 expression and the CRC TME index did not exhibit statistical significance (P > 0.05). However, RPL22L1 knockdown experiments revealed a substantial suppression of growth and migratory capacities in CRC cells RKO and HCT116 (P < 0.05). Flow cytometry analysis exhibited that on RPL22L1 knockdown, a remarkable arrest of the G1 and S phases of the cell cycle (P < 0.05) occurred. In addition, a remarkable elevation in the level of cell apoptosis was observed (P < 0.001). RNAseq exhibited that cell cycle, DNA replication, and mechanistic target of rapamycin (mTOR) complex 1pathway were inhibited after RPL22L1 knockdown, whereas the apoptosis pathway was activated (P < 0.05). Validation through RT-qPCR and western blot analysis also corroborated the downregulation of P70S6K, MCM3, MCM7, GADD45B, WEE1, and MKI67 expression levels, following RPL22L1 knockdown (P < 0.05). Consequent rescue experiments offered supportive evidence, indicating the involvement of the mTOR pathway in mediating the influence of RPL22L1 on the promotion of cell cycle progression. Moreover, in vivo assays involving tumor-bearing mice exhibited that diminished RPL22L1 levels led to arrested CRC growth (P < 0.05). These findings support RPL22L1 as a possible prognostic and therapeutic target in CRC, providing novel insights into the development of anticancer medications.

[Down-Regulation of Receptor-Tyrosine-kinase-like Orphan Receptor 1 Suppresses Cell Growth and Enhances Apoptosis in Human Colorectal Carcinoma].

ROR-α-1 Inhibits the Proliferation, Invasion, and Migration of Hepatocellular Carcinoma MHCC97H Via Downregulation of Chemokine CXCL5.

ROR1-AS1 Promotes Tumorigenesis of Colorectal Cancer Via Targeting Wnt/β-catenin.

ROR1 Expression As a Biomarker for Predicting Prognosis in Patients with Colorectal Cancer

Nuclear Receptor Retinoid-Related Orphan Receptor Alpha Promotes Apoptosis but is Reduced in Human Gastric Cancer.

OSR1 downregulation indicates an unfavorable prognosis and activates the NF-κB pathway in ovarian cancer

Knockdown of the Novel Proteasome Subunit Adrm1 Located on the 20q13 Amplicon Inhibits Colorectal Cancer Cell Migration, Survival and Tumorigenicity.

ROR1 Expression Correlated with Poor Clinical Outcome in Human Ovarian Cancer

[Silencing of Adrm1 by RNA Interference Suppresses Proliferation of Colorectal Cancer Cells].

Down-regulation of Long Non-Coding RNA RP11-708H21.4 is Associated with Poor Prognosis for Colorectal Cancer and Promotes Tumorigenesis Through Regulating AKT/mTOR Pathway.

RRS1 Silencing Suppresses Colorectal Cancer Cell Proliferation and Tumorigenesis by Inhibiting G2/M Progression and Angiogenesis

Knockdown of ribosomal protein L22-like 1 arrests the cell cycle and promotes apoptosis in colorectal cancer

High Expression of ROR2 in Cancer Cell Correlates with Unfavorable Prognosis in Colorectal Cancer.

Pathological significance of abnormal recepteur d'origine nantais and programmed death ligand 1 expression in colorectal cancer

Silencing Of Cxcr7 Gene Represses Growth And Invasion And Induces Apoptosis In Colorectal Cancer Through Erk And Beta-Arrestin Pathways

ROR1 associates unfavorable prognosis and promotes lymphoma growth in DLBCL by affecting PI3K/Akt/mTOR signaling pathway.

ORMDL1 is upregulated and associated with favorable outcomes in colorectal cancer

Up-regulation of ROR2 is Associated with Unfavorable Prognosis and Tumor Progression in Cervical Cancer.

Upregulation of Long Non-Coding RNA ROR1-AS1 Promotes Cell Growth and Migration in Bladder Cancer by Regulation of Mir-504

ROR1-AS1: A Meaningful Long Noncoding RNA in Oncogenesis

ERO1α promotes the proliferation and inhibits apoptosis of colorectal cancer cells by regulating the PI3K/AKT pathway